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To the Editor,
Aspirin plus metoclopramide, an antiemetic and prokinetic
drug, for acute migraine treatment was introduced by
Marcia Wilkinson at The City of London Migraine Clinic
[1] and until the advent of sumatriptan, it was in several
countries the standard treatment for migraine, see [2].
Sumatriptan, subcutaneous 6 mg and oral 100 mg, was
introduced in 1991 [3]. Subcutaneous sumatriptan 6 mg
resulted in headache relief (HR) (a decrease of headache
from moderate or severe to none or mild) in 70–72% after
1h[ 4, 5] and 86% after 2 h [4].Oral sumatriptan 100 mg
(56% HR) was not superior to the oral combination of
aspirin 1,000 mg and metoclopramide (ASP ? M)10 mg
(45%) in the ﬁrst attack treated, but sumatriptan was better
than the combination in the second and third attack [6].
From 1993 to 1994, a randomised, controlled trial
(RCT) was performed in France. It had the title: ‘‘A ran-
domised, multicentre, double-blind, double-dummy, par-
allel-group study to compare the efﬁcacy and safety of
subcutaneous sumatriptan with oral aspirin plus oral met-
oclopramide in the acute treatment of migraine’’ [7].
It was performed in 46 centres in France and showed, as
expected, that subcutaneous sumatriptan 6 mg was superior
(p\0.001) to efferverscent aspirin 1,000 mg plus meto-
clopramide 10 mg from 30 to 120 min, see Table 1. Sub-
cutaneous sumatriptan 6 mg was successful in 84% of
patients at 2 h and similar results were reported in one
pivotal RCT (86%) on subcutaneous sumatriptan [4]. The
headache relief for ASP ? M was 62% and somewhat
higher than the 45% observed in a comparative RCT [6],
see above, but in the range of the 56% headache relief
observed in two other RCTs, with highly soluble lysine
acetylsalicylate plus metoclopramide [8, 9]. The relative
high-headache response for ASA ? M could be due to the
use of effervescent aspirin [7].
The rationale for doing this RCT remains obscure. Why
should an injection of an antimigraine drug (the optimal
route of administration) be compared with an oral form of
another antimigraine drug (a suboptimal form because of
slower absorption)? The most likely reason is that this RCT
was done solely for registration purposes in France. We
don’t know whether it was done at the request of the
French health authorities. Any way, this RCT, even if
based only on the summary, was of good quality and the
Table 1 Headache relief (HR) and therapeutic gain (percentage HR
after subcutaneous sumatriptan 6 mg minus percentage HR after
effervescent aspirin 1,000 mg plus metoclopramide) for the ﬁrst-
treated migraine attack
Sumatriptan
(n = 122)
ASP ? M
(n = 125)
Headache relief after 30 min
Yes 62 (50%) 31 (24%)
No 62 (50%) 96 (76%)
Therapeutic gain 26% (95% CI 14–37%)
Headache relief after 60 min
Yes 87 (71%) 57 (45%)
No 35 (29%) 69 (55%)
Therapeutic gain 26% (95% CI 14–38%)
Headache relief after 120 min
Yes 99 (84%) 79 (62%)
No 19 (16%) 48 (38%)
Therapeutic gain 22% (95% CI 11–32%)
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DOI 10.1007/s10194-011-0312-xRCT remains unpublished 17 years later. Publication is an
obligation of the clinical investigators [10] and this RCT
should have been published many years ago.
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